Healthcare / Drug Manufacturers - Specialty & GenericBSE
$44.95
+1.22 (+2.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $56.3M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
26.6x
↑ROE
-1.1%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+1.0%
FCF CAGR
-49.3%
FCF margin
4.8%
FCF / Net income
-1.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $395.6M · net income $-10.7M · FCF $18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $395.6M | $395.6M | $389.8M | $367.6M | $383.5M |
| Net Income | $-10.7M | $-10.7M | $56.1M | $83.0M | $115.9M |
| EBITDA | $91.9M | $91.9M | $141.8M | $182.3M | $217.9M |
| EPS | — | — | 0.92 | 1.36 | 1.90 |
| Gross Margin | 100.0% | 100.0% | 97.8% | 88.6% | 90.7% |
| Operating Margin | 5.2% | 5.2% | 18.5% | 16.6% | 24.7% |
| Net Margin | -2.7% | -2.7% | 14.4% | 22.6% | 30.2% |
| Balance Sheet | |||||
| Current Ratio | 3.40 | 3.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $18.8M | $18.8M | $56.3M | $75.9M | $144.3M |
| Returns | |||||
| ROE | -1.1% | -1.1% | 5.8% | 9.2% | 14.1% |
| Valuation | |||||
| P/E | — | — | 68.32 | — | — |
| EV/EBITDA | 26.56 | 26.56 | 25.17 | — | — |
| P/B | 2.88 | 2.88 | 3.99 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 1.5% | 1.5% | 6.0% | -4.1% | — |
| EPS Growth | — | — | -32.4% | -28.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.92 → n/d
Residual
-28.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.